denali therapeutics inc. (“denali”) is a biotechnology company focused on the discovery and development of therapies for patients with neurodegenerative diseases, including alzheimer’s disease, parkinson’s disease, als and others. denali was founded by scientists, industry experts and investors who share the vision that recent scientific insights into the genetic causes and biological processes underlying neurodegenerative disease, together with new translational medicine tools, offer an unprecedented opportunity to discover and develop effective medicines. denali is rigorously pursuing a science-driven approach to translational medicine and clinical development. founding investors include fidelity biosciences, arch venture partners, flagship ventures and the alaska permanent fund (represented by crestline investors).
![Denali Therapeutics logo](/files/LOGO/1714899-DNLI.png)
Company profile
Ticker
DNLI
Exchange
Website
CEO
Ryan Watts
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Denali BBB Holding Limited • Denali Therapeutics CH GmbH ...
DNLI stock data
Latest filings (excl ownership)
8-K
Submission of Matters to a Vote of Security Holders
31 May 24
10-Q
2024 Q1
Quarterly report
7 May 24
8-K
Denali Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
7 May 24
ARS
2023 FY
Annual report to shareholders
18 Apr 24
DEFA14A
Additional proxy soliciting materials
18 Apr 24
DEF 14A
Definitive proxy
18 Apr 24
S-3ASR
Automatic shelf registration
22 Mar 24
D
$499.73 mm in equity / options, sold $499.73 mm, 11 investors
1 Mar 24
S-8
Registration of securities for employees
27 Feb 24
10-K
2023 FY
Annual report
27 Feb 24
Latest ownership filings
4
Steve E. Krognes
3 Jul 24
4
VICKI L SATO
3 Jul 24
144
Notice of proposed sale of securities
1 Jul 24
144
Notice of proposed sale of securities
1 Jul 24
4
Jennifer E. Cook
10 Jun 24
144
Notice of proposed sale of securities
6 Jun 24
4
Steve E. Krognes
4 Jun 24
4
Nancy Thornberry
4 Jun 24
4
Marc Tessier-Lavigne
4 Jun 24
4
VICKI L SATO
4 Jun 24
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 62.15 mm | 62.15 mm | 62.15 mm | 62.15 mm | 62.15 mm | 62.15 mm |
Cash burn (monthly) | 22.18 mm | 623.50 k | 39.24 mm | 16.13 mm | 37.87 mm | 34.40 mm |
Cash used (since last report) | 85.74 mm | 2.41 mm | 151.69 mm | 62.37 mm | 146.42 mm | 132.99 mm |
Cash remaining | -23.59 mm | 59.74 mm | -89.54 mm | -221.29 k | -84.27 mm | -70.84 mm |
Runway (months of cash) | -1.1 | 95.8 | -2.3 | -0.0 | -2.2 | -2.1 |
Institutional ownership, Q1 2024
13F holders | Current |
---|---|
Total holders | 202 |
Opened positions | 79 |
Closed positions | 35 |
Increased positions | 48 |
Reduced positions | 55 |
13F shares | Current |
---|---|
Total value | 2.28 tn |
Total shares | 148.34 mm |
Total puts | 90.30 k |
Total calls | 142.00 k |
Total put/call ratio | 0.6 |
Largest owners | Shares | Value |
---|---|---|
Baillie Gifford & Co | 14.04 mm | $288.13 bn |
BIIB Biogen | 12.75 mm | $0.00 |
BLK Blackrock | 12.20 mm | $250.34 bn |
Vanguard | 10.97 mm | $225.07 bn |
ARCH Venture Fund VIII | 10.67 mm | $893.61 mm |
Wellington Management | 8.27 mm | $169.70 bn |
Douglas K Bratton | 6.86 mm | $0.00 |
STT State Street | 6.32 mm | $129.77 bn |
Capital Research Global Investors | 6.05 mm | $124.15 bn |
Temasek | 5.71 mm | $117.09 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
1 Jul 24 | Sato Vicki L | Common Stock | Sell | Dispose S | No | Yes | 22.86 | 100 | 2.29 k | 119,256 |
1 Jul 24 | Sato Vicki L | Common Stock | Sell | Dispose S | No | Yes | 22.12 | 2,980 | 65.92 k | 119,356 |
1 Jul 24 | Krognes Steve E. | Common Stock | Sell | Dispose S | No | Yes | 22.8 | 100 | 2.28 k | 34,404 |
1 Jul 24 | Krognes Steve E. | Common Stock | Sell | Dispose S | No | Yes | 22.12 | 29,900 | 661.39 k | 34,504 |
13 Jun 24 | Krognes Steve E. | Common Stock | Sell | Dispose S | No | No | 21.79 | 688 | 14.99 k | 52,620 |
6 Jun 24 | Cook Jennifer E. | Common Stock | Sell | Dispose S | No | Yes | 21.73 | 1,458 | 31.68 k | 20,038 |
31 May 24 | Peter S Klein | Common Stock | Grant | Acquire A | No | No | 0 | 5,967 | 0.00 | 21,496 |
31 May 24 | Peter S Klein | Stock Option Common Stock | Grant | Acquire A | No | No | 18.56 | 17,901 | 332.24 k | 17,901 |
31 May 24 | Erik Harris | Common Stock | Grant | Acquire A | No | No | 0 | 5,967 | 0.00 | 17,052 |
31 May 24 | Erik Harris | Stock Option Common Stock | Grant | Acquire A | No | No | 18.56 | 17,901 | 332.24 k | 17,901 |
News
JP Morgan Maintains Overweight on Denali Therapeutics, Raises Price Target to $29
10 Jul 24
Stericycle, MarineMax, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Monday
3 Jun 24
Denali Therapeutics Says FDA Has Selected DNL126 For Participation In Support For Clinical Trials Advancing Rare Disease Therapeutics Pilot Program
3 Jun 24
Louisiana-Pacific Posts Upbeat Results, Joins Cricut, Elanco Animal, American Public Education And Other Big Stocks Moving Higher On Wednesday
8 May 24
Wedbush Maintains Outperform on Denali Therapeutics, Lowers Price Target to $30
8 May 24
Press releases
Flagship Pioneering and ProFound Therapeutics Announce Agreement to Identify Novel First-in-Class Therapeutics for the Treatment of Obesity under Strategic Partnership with Pfizer
12 Jun 24
Denali Therapeutics Announces FDA Has Selected DNL126 (ETV:SGSH) for MPS IIIA (Sanfilippo Syndrome Type A) for START Pilot Program Intended to Accelerate Development of Rare Disease Therapies
3 Jun 24
Denali Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
7 May 24
Flagship Pioneering Unveils Prologue Medicines to Unlock the Therapeutic Potential of the Viral Proteome
7 May 24